Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Mithracin
Synonyms :
Plicamycin
Class :
Antineoplastic Agents and RNA synthesis inhibitor
Brand Name :
Mithracin
Synonyms :
Plicamycin
Class :
Antineoplastic Agents and RNA synthesis inhibitor
Dosage forms & strengthsÂ
Solution for injection   Â
2.5 mg    Â
It is used for malignant tumors of the testis where the treatment by surgery/radiation is unsuccessful :
25 - 30
mcg
or 0.025-0.030 mg/kg
Continue the treatment for 8-10 days until disease progression or unacceptable toxicity occurs
Therapy should not exceed more than ten daily doses
The individual daily dose should not exceed 0.030 mg/kg
0.025
mg/kg
once a day
3 - 4
days
0.025 mg/kg per day for 3 or 4 days
0.025
mg/kg
once a day
3 - 4
days
0.025 mg/kg per day for 3 or 4 days
measles, mumps, rubella, and varicella vaccine, live (Rx)
may diminish the therapeutic effect
measles mumps and rubella vaccine, live
may diminish the therapeutic effect
may diminish the therapeutic effect
smallpox (vaccinia) vaccine, live
may diminish the therapeutic effect
may diminish the therapeutic effect
respiratory syncytial virus vaccine, adjuvanted
may decrease the therapeutic effect when combined with vaccine
respiratory syncytial virus (RSV) vaccine
may decrease the therapeutic effect when combined with vaccine
poliovirus vaccine, live, trivalent
may decrease the therapeutic effect when combined with vaccine
poliovirus vaccine inactivated
may decrease the therapeutic effect when combined with vaccine
may have an increased nephrotoxic effect when combined with aminoglycosides
neomycin/polymyxin B/bacitracin topical
may have an increased nephrotoxic effect when combined with aminoglycosides
may have an increased nephrotoxic effect when combined with aminoglycosides
may have an increased nephrotoxic effect when combined with aminoglycosides
may have an increased nephrotoxic effect when combined with aminoglycosides
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
may decrease the therapeutic effect when combined with bacillus clausii
sodium picosulfate, citric acid, and magnesium oxideÂ
may decrease the therapeutic effect when combined with sodium picosulfate
may decrease the therapeutic effect when combined with typhoid vaccine
antibiotics: they may decrease the therapeutic effect of sodium picosulfuric acid
meningococcal A C Y and W-135 diphtheria conjugate vaccine
may decrease the therapeutic effect of Antibiotics
may decrease the therapeutic effect of Antibiotics
may decrease the therapeutic effect of Antibiotics
may decrease the therapeutic effect of Antibiotics
may decrease the therapeutic effect of Antibiotics
When both drugs are combined, there may be an increased risk of bleeding and sometimes fatal hemorrhage  
When both drugs are combined, there may be an increased risk of bleeding and fatal hemorrhage  
When both drugs are combined, there may be an increased risk of bleeding and sometimes fatal hemorrhage  
When both drugs are combined, there may be an increased risk of severe and potentially fatal infections  
When both drugs are combined, there may be a decreased therapeutic effect of the vaccine  
When both drugs are combined, there may be an increased risk of bleeding and sometimes fatal hemorrhage  
When both drugs are combined, there may be an increased risk of bleeding and fatal hemorrhage  
When both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections  
When both drugs are combined, there may be an increased risk of bleeding and sometimes fatal hemorrhage  
When both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections  
When both drugs are combined, there may be an increased risk of bleeding and fatal hemorrhage  
may decrease the therapeutic effect when combined with bcg
may decrease the therapeutic effect when combined with cholera vaccine
antibiotics decrease the efficacy of BCG intravesical
it decreases the efficacy of antibiotics
When both drugs are combined, there may be a decreased therapeutic effect of the vaccine  
When both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections  
When both drugs are combined, there may be an increased risk of severe and possibly life-threatening infections  
When both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections  
When both drugs are combined, there may be an increased risk of adverse effects  
When both drugs are combined, there may be an increased risk of adverse effects  
When both drugs are combined, there may be a decreased therapeutic effect of the vaccine  
When both drugs are combined, there may be an increased risk of bleeding  
When both drugs are combined, there may be an increased risk of bleeding  
When both drugs are combined, there may be an increased risk of bleeding  
When both drugs are combined, there may be an increased risk of bleeding  
may decrease the therapeutic effect when combined with immune checkpoint inhibitors
may decrease the therapeutic effect when combined with immune checkpoint inhibitors
may decrease the therapeutic effect when combined with immune checkpoint inhibitors
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may decrease the therapeutic effect when combined with immune checkpoint inhibitors
may decrease the therapeutic effect when combined with immune checkpoint inhibitors
may decrease the therapeutic effect when combined with immune checkpoint inhibitors
may decrease the therapeutic effect when combined with lactobacillus and estriol
BCG Vaccine live: they may decrease the therapeutic effect of antibiotics
When both drugs are combined, there may be a decreased plasma concentrations of oral quinolone antibiotics  
when both drugs are combined, there may be a decreased plasma concentrations of oral quinolone antibiotics 
antibiotics decrease the efficacy of thiamine by altering the gut flora
Actions and spectrum: Â
Action:Â
Plicamycin kills cancer cells by binding to DNA and stopping RNA synthesis. It’s used for testicular cancer, osteosarcoma, and hypercalcemia in cancer. Also studied for treating Paget’s disease and some endocrine disorders.Â
Frequency not defined  Â
Bloody stools  Â
Swelling of face  Â
Nose bleeding  Â
Skin rash  Â
Sore throat  Â
Bruising  Â
Vomiting of blood  Â
Yellow eyes or skin  Â
Drowsiness  Â
Fever  Â
Headache  Â
Black Box Warning: Â
Plicamycin has a serious warning for severe toxicity, including effects on the blood, liver, kidneys, and gastrointestinal system.Â
Contraindication/Caution: Â
Contraindication: Â
HypersensitivityÂ
Pregnancy & breastfeedingÂ
Bone Marrow SuppressionÂ
Caution: Â
Hematologic disturbancesÂ
Gastrointestinal disturbancesÂ
ExtravasationÂ
Pregnancy warnings:    Â
US FDA pregnancy category: X Â
Breastfeeding warnings: Â
The release of the drug into the human breastmilk is unknown  Â
Pregnancy Categories:      Â
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first trimester or the later trimester      Â
<b>Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women      Â
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women      Â
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits      Â
Category X: Drugs listed in this category outweigh risks over benefits Hence these categories of drugs need to be avoided by pregnant women      Â
Category N: There is no data available for the drug under this category   Â
Pharmacology: Â
Plicamycin fights cancer by binding to DNA, blocking RNA production, and disrupting cancer cell transcription.Â
Pharmacodynamics: Â
Plicamycin kills cancer cells by binding to DNA and stopping RNA synthesis. It’s used for testicular cancer, osteosarcoma, and hypercalcemia in cancer. Also studied for treating Paget’s disease and some endocrine disorders.Â
Pharmacokinetics: Â
AbsorptionÂ
Plicamycin is given through IV because it’s poorly absorbed orally, quickly reaching the bloodstream to work.Â
DistributionÂ
Plicamycin distributed throughout the body, crosses the blood-brain barrier, and reaches different tissues and organs, binding mostly to albumin in the plasma.Â
MetabolismÂ
 Plicamycin is metabolized in the liver mainly by the cytochrome P450 enzyme system.Â
Excretion and EliminationÂ
Plicamycin and its metabolites are mainly removed through the liver and kidneys.Â
Administration: Â
Plicamycin is usually given through an IV because it’s not well-absorbed orally.Â
Patient Information Leaflet  Â
Generic Name: plicamycin Â
Pronounced: Plye kay mye’ sin Â
 Why do we use plicamycin? Â
For the management of testicular cancer and the hypercalcemia and hypercalciuria linked to many advanced cancer types.Â
It is used to treat Paget’s disease of the bone, testicular cancer, and, in rare cases, hypercalcemia.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
